ArticleMediators of inflammation2012
Circulating leukotriene B4 identifies respiratory complications after trauma.
Article in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: A double-blind, randomized clinical trial.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2023Trial
- Eicosanoids Signals in SARS-CoV-2 Infection: A Foe or Friend.Molecular biotechnology · 2024Review
- Exome-Wide Association Study Reveals Host Genetic Variants Likely Associated with the Severity of COVID-19 in Patients of European Ancestry.Life (Basel, Switzerland) · 2022Article
- Assessment of Polyunsaturated Fatty Acids on COVID-19-Associated Risk Reduction.Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia · 2022Review
- LTBDiabetes · 2021Article
- Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine.Frontiers in immunology · 2020Review
- Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential.The Journal of pathology · 2019Review
- Profiling inflammatory markers in patients with pneumonia on intensive care.Scientific reports · 2018Article
- Differential Expression of Inflammation-Related Genes in Children with Down Syndrome.Mediators of inflammation · 2016Article
- Leukotriene B4-Neutrophil Elastase Axis Drives Neutrophil Reverse Transendothelial Cell Migration In Vivo.Immunity · 2015Article
- The Role of Omega-3 Polyunsaturated Fatty Acids in the Treatment of Patients with Acute Respiratory Distress Syndrome: A Clinical Review.BioMed research international · 2015Review
- Inducible protein-10, a potential driver of neurally controlled interleukin-10 and morbidity in human blunt trauma.Critical care medicine · 2014Article
- The effects of exogenous surfactant administration on ventilation-induced inflammation in mouse models of lung injury.BMC pulmonary medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukotriene B4 (LTB4), a proinflammatory lipid mediator correlates well with the acute phase of Acute Respiratory Distress Syndrome (ARDS). Therefore, LTB4-levels were investigated to determine whether they might be a useful clinical marker in predicting pulmonary complications (PC) in multiply traumatized patients.
methodsPlasma levels of LTB4 were determined in 100 patients on admission (ED) and for five consecutive days (daily). Twenty healthy volunteers served as control. LTB4-levels were measured by ELISA. Thirty patients developed PC (pneumonia, respiratory failure, acute lung injury (ALI), ARDS, pulmonary embolism) and 70 had no PC (ØPC).
resultsLTB4-levels in the PC-group [127.8 pg/mL, IQR: 104-200pg/ml] were significantly higher compared to the ØPC-group on admission [95.6 pg/mL, IQR: 55-143 pg/mL] or control-group [58.4 pg/mL, IQR: 36-108 pg/mL]. LTB4 continuously declined to basal levels from day 1 to 5 without differences between the groups. The cutoff to predict PC was calculated at 109.6 pg/mL (72% specificity, 67% sensitivity). LTB4 was not influenced by overall or chest injury severity, age, gender or massive transfusion. Patients with PC received mechanical ventilation for a significantly longer period of time, and had prolonged intensive care unit and overall hospital stay.
conclusionHigh LTB4-levels indicate risk for PC development in multiply traumatized patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.